ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Survival differences between HER2-0 and HER2-low-expressing breast cancer- A meta-analysis of early breast cancer patients

Yang, Ciqiu; Zhang, Xiaoqi; Chen, Yitian; Li, Peiyong; Zhang, Junsheng; Xu, Aiqi; Huang, Na; Liang, Minting; Chen, Yilin; Wang, Kun*广东省人民医院; 广东医学院; 广州大学; 南方医科大学; 汕头大学
Critical Reviews in Oncology/Hematology2023-5DOI: 10.1016/j.critrevonc.2023.103962
4被引11阅读
引用收藏
分享

摘要

Background: HER2-low (human epidermal growth factor receptor 2) breast cancer takes up 40-50% in all breast cancer subtypes. The survival difference between HER2-low and HER2-zero breast cancers remain uncertain. Therefore, the aim of this study was to compare survival outcome of the two subtypes and to explore the impact of hormone receptor status. Methods: A comprehensive medical literature search was performed by searching PubMed, EMBASE, and the Cochrane Libraries up to August 2022. We included observational studies reporting hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). The results of individual studies were pooled by random-effects models using Stata 16.0. Seventeen articles with a total of 78984 breast cancer patients were included in the meta-analysis. Results: We observed a statistically significant association between low HER2 expression and better breast cancer survival outcomes (OS: HR: 0.83; 95% confidence interval: 0.75, 0.90; DFS/RFS: HR: 0.83; 95% confidence interval: 0.75, 0.91). In a subgroup analysis, we found that HER2-low patients had better survival outcomes relative to hormone receptor-positive breast cancer patients (OS: HR: 0.87; 95% confidence interval: 0.81, 0.93; DFS/RFS: HR: 0.91; 95% confidence interval: 0.85, 0.96). Similarly, in triple-negative breast cancer patients, we also observed a positive association between HER2 low expression and better survival (OS: HR: 0.85; 95% confidence interval: 0.71, 0.98; DFS/RFS: HR: 0.85; 95% confidence interval: 0.74, 0.95). Conclusions: Our study showed that HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer, regardless of hormone receptor status. Registration: This meta-analysis was registered with PROSPERO (CRD42022335704) on June 10, 2022. Availability of data and materials: All data generated or analysed during this study are included in this published article [and its supplementary information files].

学科与关键词

关键词
HER2-low-expressing breast cancerHER2-zero breast cancerSurvival
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Critical Reviews in Oncology/Hematology
发表日期
2023-05
卷期
第 185 卷
页码
103962
DOI
10.1016/j.critrevonc.2023.103962
语言
ENGLISH
成果收录
SCIE

作者

  • Y

    Yang, Ciqiu (第一作者)

    123 · guangdong prov peoples hosp · southern med univ

  • Z

    Zhang, Xiaoqi

    123 · guangdong prov peoples hosp · southern med univ · 2

查看全部 10 位作者收起作者
  • C

    Chen, Yitian

    123 · guangdong prov peoples hosp · southern med univ

  • L

    Li, Peiyong

    123 · guangdong prov peoples hosp · southern med univ · guangdong med univ

  • Z

    Zhang, Junsheng

    123 · guangdong prov peoples hosp · southern med univ

  • X

    Xu, Aiqi

    guangzhou univ

  • H

    Huang, Na

    2 · southern med univ

  • L

    Liang, Minting

    shantou univ · 123 · guangdong prov peoples hosp · southern med univ

  • C

    Chen, Yilin

    guangzhou univ

  • W

    Wang, Kun (通讯)

    123 · guangdong prov peoples hosp · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417